Antag Therapeutics CEO Alexander Sparre-Ulrich (L) and Versant's Alex Mayweg
December 4, 2024 03:00 AM EST
Financing
Startups

On heels of Mar­i­Tide da­ta, Dan­ish obe­si­ty biotech dis­clos­es €80M Se­ries A

Kyle LaHucik

Senior Reporter

Ver­sant is out with its third obe­si­ty biotech of the year, lead­ing an €80 mil­lion Se­ries A for An­tag Ther­a­peu­tics, a Dan­ish com­pa­ny de­vel­op­ing a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: CEO of Unit­ed­Health in­sur­ance unit shot and killed in New York in what po­lice call ‘a brazen, tar­get­ed ...

Lil­ly beats No­vo in bell­wether head-to-head weight loss study

As 23andMe strug­gles, an­oth­er ge­net­ic test­ing com­pa­ny bets on drug dis­cov­ery

GSK makes an­oth­er ADC deal, this time with BioN­Tech's part­ner Du­al­i­ty­Bio

Lil­ly drops body mass ranges from FDA la­bel for weight loss drug

Blue­bird and Ver­tex's sick­le cell gene ther­a­pies to kick off new Med­ic­aid ac­cess mod­el

A service from the Financial Times